Achieve Life Sciences (ACHV)

Overall impact
B (63)

Commentary

Achieve Life Sciences is a strong overall performer. With a 'B' rating of 62.7 for overall impact (69th percentile compared to all companies), Achieve Life Sciences ranks 414th out of 650 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 410 others, and ahead of Viking Therapeutics, Kadmon, Madrigal Pharmaceuticals and 233 others. On top material causes for Achieve Life Sciences's industry (Biotechnology), Achieve Life Sciences performs well in Reduced Use of tobacco (89.0 score), Child and Maternal Health (93.1), Child and Maternal Health (94.9) and 19 other causes where it received an 'A' score and performs poorly in Accountable Institutions (32.7 score), Accountable Institutions (32.7), Accountable Institutions (32.7) and 15 other causes where it received a 'D' or 'F' score.
Impact
Cause ACHV
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1991
Employees
28
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Wa, United States
Share classes
ACHV
Description
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company that develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain, which helps reduce the severity of nicotine withdrawal symptoms. Achieve Life Sciences, Inc. has a license and supply agreement with Sopharma AD and the University of Bristol. The company is headquartered in Vancouver, Canada.
Material causes
Ethos considers the following causes material for Achieve Life Sciences, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.